Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Susana Maria Campos, M.D.

TitleAssistant Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
D1242
44 Binney St
Boston MA 02115
Phone617/632-5874
Fax617/632-3479

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, Lurain JR, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M. Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 1; 11(3):320-43.
    View in: PubMed
  2. Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
    View in: PubMed
  3. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
    View in: PubMed
  4. Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
    View in: PubMed
  5. Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
    View in: PubMed
  6. Campos SM, Dizon DS. Antimitotic inhibitors. Hematol Oncol Clin North Am. 2012 Jun; 26(3):607-28, viii-ix.
    View in: PubMed
  7. Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
    View in: PubMed
  8. Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
    View in: PubMed
  9. Parithivel K, Jagannathan JP, Krajewski K, O'Regan K, Quick CM, Ramaiya N, Campos S. Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer Imaging. 2011; 11:67-9.
    View in: PubMed
  10. Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical cancer. J Natl Compr Canc Netw. 2010 Dec; 8(12):1388-416.
    View in: PubMed
  11. Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, Giuliano A, Jones HW, Lele SM, Lieberman RW, Massad SL, Morgan MA, Reynolds RK, Rhodes HE, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. Cervical cancer screening. J Natl Compr Canc Netw. 2010 Dec; 8(12):1358-86.
    View in: PubMed
  12. Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
    View in: PubMed
  13. Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010; 2010:149362.
    View in: PubMed
  14. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 1; 28(1):154-9.
    View in: PubMed
  15. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
  16. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
    View in: PubMed
  17. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W, Teng N. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):498-531.
    View in: PubMed
  18. Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7.
    View in: PubMed
  19. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44.
    View in: PubMed
  20. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 1; 14(23):7871-7.
    View in: PubMed
  21. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
    View in: PubMed
  22. Campos SM. Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 2008 Oct; 26(8):757-68.
    View in: PubMed
  23. Cervantes A, Roselló S, Rodríguez-Braun E, Navarro S, Campos S, Hernández A, García-Granero E. Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol. 2008 Sep; 19 Suppl 7:vii266-72.
    View in: PubMed
  24. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
    View in: PubMed
  25. N.S.Horowitz, R.T.Penson, S.M.Campos, J.Lee, D.L.Kendall, C.N.Krasner, S.T.Berlin, M.Roche, L.R.Duska, U.A.Matulonis. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. 2008; 26(ASCO 2008):A: 5523.
  26. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W, Teng N. Cervical cancer. J Natl Compr Canc Netw. 2008 Jan; 6(1):14-36.
    View in: PubMed
  27. K.Mirabeale, A.B.Kornblith, R.T. Penson, H.Lee, A.Goodman, S.M.Campos, L.R.Duska, L.Pereira, C.D.Gibson, U.A.Matulonis. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. 2008; 26(ASCO 2008):A:5528.
  28. M.C.Castells, N.M.Tennant, D.E.Sloane, F.I.Hsu, S.T.Berlin, S.M.Campos, U.A.Matulonis. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intervenous and intraperitoneal desensitizations in 413 cases. 2008; 26(ASCO 2008):A:5526.
  29. Partridge EE, Abu-Rustum N, Campos S, Fahey PJ, Greer BE, Lele SM, Lieberman RW, Lipscomb GH, Morgan M, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. Cervical cancer screening. J Natl Compr Canc Netw. 2008 Jan; 6(1):58-82.
    View in: PubMed
  30. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24.
    View in: PubMed
  31. Cervantes A, Rodríguez-Braun E, Navarro S, Hernández A, Campos S, García-Granero E. Integrative decisions in rectal cancer. Ann Oncol. 2007 Jul; 18 Suppl 9:ix127-31.
    View in: PubMed
  32. A.Viswanathan, N.Horick, C.Tanaka, S.Campos, U.Matulonis, R.Berkowitz. Chemotherapy and radiation therapy UPSC. 2007; 25(ASCO 2007):A:5535.
  33. S.M.Campos, D.S.Dizon, S.A.Cannistra, M.Roche, C.N.Krasner, S.T.Berlin, N.S.Horowitz, P. DiSilvestro, U.A.Matulonis, R.T.Penson. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarin and mullerian cancers. 2007; 25(ASCO 2007):A:5517.
  34. Cervantes A, Chirivella I, Rodriguez-Braun E, Campos S, Navarro S, García Granero E. A multimodality approach to localized rectal cancer. Ann Oncol. 2006 Sep; 17 Suppl 10:x129-34.
    View in: PubMed
  35. Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
    View in: PubMed
  36. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Jaggernauth W, Jhingran A, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan RJ, Nag S, Partridge EE, Powell CB, Remmenga SW, Reynolds RK, Small W, Soper J, Teng N. Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62.
    View in: PubMed
  37. Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
    View in: PubMed
  38. S.M.Campos, L.Parker, W.Chen, C.A.Bunnell, T.Atkinson, J.Lee, U.A.Matulonis, L.N.Harris, C.N. Krasner. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractoy gynecological malignancies or metastatic breast cancer. 2006; 24(ASCO 2006):A:5085.
  39. R.T.Penson, S.A.Cannistra, M.V.Seiden, C.N.Krasner, U.A.Matulonis, N.S.Horowitz, S.T.Berlin, D.S.Dizon, H.Lee, S.M.Campos, n.representing members of the Dana-Farber Harvard Cancer Institute. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. 2006; 24(ASCO 2006):A:5020.
  40. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
    View in: PubMed
  41. Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):807-16.
    View in: PubMed
  42. Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005 Aug 20; 23(24):5597-604.
    View in: PubMed
  43. Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
    View in: PubMed
  44. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
    View in: PubMed
  45. S.Vukelija, J.O'Shaughnessy, S.M.Campos, L. Vahdat, J.Blum, D.Yardley, P.Mainwaring, F.Senecal, R.Benner, L.Denis, E.Perez. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. 2005; 23(ASCO 2005):A:562.
  46. R.T.Penson, C.N.Krasner, M.V.Seiden, T.Atkinson, S.M.Campos, A.Klein, U.Matulonis. Long-acting octreotide (Sandostatin LAR Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. 2005; 23(ASCO 2005):A:5191.
  47. Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
    View in: PubMed
  48. Campos SM. Evolving treatment approaches for early breast cancer. Breast Cancer Res Treat. 2005; 89 Suppl 1:S1-7.
    View in: PubMed
  49. C.Lee, U.A.Matulonis, S.M.Campos, A.H.Gross, C.M.Hayes, K.T.Keenan, M.C.Castells, . Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecological malignancies. 2005; 23(ASCO 2005):A:5090.
  50. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005 Jan; 96(1):10-8.
    View in: PubMed
  51. U.A.Matulonis, S.M.Campos, C.Krasner, L.Duska, R.P.Penson, R.Falke, M.Roche, L.M.Smith, H.Lee, M.V.Seiden. A phase II trial of modified triple doublets for the treatment of advanced Mullerian malignancies. 2005; 23(ASCO 2005):A:5010.
  52. Teng N, Abu-Rustum NR, Bahador A, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Fiorica J, Greer BE, Kapp DS, Kavanagh J, Koh WJ, Kuettel M, Lurain JR, Molpus KL, Nag S, Partridge EE, Powell CB, Reynolds RK, Small W, Soper J, Tillmanns TD. Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):612-30.
    View in: PubMed
  53. Partridge EE, Abu-Rustum NR, Campos S, Edelson M, Fahey PJ, Fiorica J, Greer BE, Lieberman RW, Likes W, Molpus KL, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Soper J, Teng N, Trimble CL, Wilczynski S. Cervical cancer screening clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):570-87.
    View in: PubMed
  54. Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
    View in: PubMed
  55. S.M.Campos, M.V.Seiden, A.Oza, M.Plante, R.Potkul, O.Hamid, P.Lenehan, E.Kaldjian, C.Jordan, H.Hirte; Dana-Farber, Boston,MA; MAssachusetts General Hospital, Boston,MA; Princess Margaret, Toronto,ON, Canada; Pavilion L'Hotel-Dieu de Quebec, Quebec City, PQ, Canada; Loyola University Medical Center, Chicago IL; Pfizer, Inc, Ann Arbor, MI; Hamilton CAncer Center, Hamilton, ON, Canada. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 2004; 22(ASCO 2004):A:5054.
  56. D.A. Cameron, E.Winer, S.C.Campos, J.-P. Guastalla; Western General Hospital, Edinburgh, United Kingdom; Dana-Farber, Boston,MA; Centre Leon Berard, Lyon, France. A comparative study of exemestane versus anastroxole in post-metopausal breast cancer subjects aith visceral disease. 2004; 22(ASCO 2004):A:628.
  57. R.T. Penson, M.V.Seiden, S.M.Campos, C.N.Krasner, A.F.Fuller, A.Goodman, M.Roche, A.Willman, A.Muzikansky, U.A.Matulonis; Massachusetts General Hospital, Boston,MA; Dana-Farber Cancer Institute, Boston,MA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Mullerian tumors. 2004; 22(ASCO 2004):A:5151.
  58. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004; 9(2):126-36.
    View in: PubMed
  59. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
    View in: PubMed
  60. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
    View in: PubMed
  61. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 1; 21(15):2889-95.
    View in: PubMed
  62. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist. 2003; 8 Suppl 2:10-6.
    View in: PubMed
  63. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99.
    View in: PubMed
  64. U.MAtulonis, S.C.Campos, M.Seiden, C.Krasner, A.Fuller, L.Duska, R.Berkowitz, T.Collela, A.Crowe, A.Goodman; Dana-FArber CAncer Institute, Boston,MA; Massachusetts General Hospital, Boston,MA; Brigham and Women's Hospital, Boston,MA. Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. 2003; 22(ASCO 2003):A:1872.
  65. S.M.Campos; Dana-Farber Cancer institute, Boston,MA. Epoetin alfa 40,000 u once weekly significantly improves hemoglobin and quality of life in anemic patients with ovarian cancer. 2003; 22(ASCO 2003):A:3111.
  66. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
    View in: PubMed
  67. Campos S. The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol. 2002 Jun; 29(3 Suppl 8):7-12.
    View in: PubMed
  68. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002 Mar 15; 20(6):1562-9.
    View in: PubMed
  69. M.O.Butler, M.Seiden, M.Mihm, S.M.Campos, L.Duska, D.Goldstein, A.Goodman, D.Neuberg, N.Nikrui, U.Matulonis, M.Muto, R.Penson, I.Webb, A.Fuller, R.Berkowitz, L.Nadler, G.Dranoff, Dana-Farber Cancer Institute,Boston,MA; Massachuesetts General Hospital,Boston,MA; Brigham and Women's Hospital,Boston,MA. A phase I of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). 2002; 21(ASCO 2002):A:1840.
  70. H.J.Burstein, P.K.Marcom, R.Lambert-Falls, K.Havlin, B.Overmoyer, R.J.Friedlander, C.H.Weissman, R.Strenger, C.L.Vogel, P.D.Ryan, M.J.Ellis, L.N.Harris, C.A.Bunnell, S.M.Campos, M.Hallor, E.P.Winer, Dana-Farber Cancer Institute, Boston,MA; Duke University Medical Center, Durham,NC; South Carolina Oncology Associates, West Columbia,SC; Evanston,IL; University Hospitals of Cleveland, Cleveland,OH; New Hampshire Oncology-Hematology, Hooksett,NH; US Oncology, Latham,NY; Miriam Hospital, Providence, RI; Columbia Cancer Research Network, Plantation, FL; Massachusetts General Hospital, Boston,MA. Multicenter phase II study of trastuzumab (Herceptin;H) and vinorelbine (Navelbine;N) as first-line therapy for HER2 overexpressing metastic breast cancer (HER2+MBC). 2002; 21(ASCO 2002):A:211.
  71. R.T.Penson, J.P.Eder, A.F.Fuller, J.G.Supko, U.Matulonis, S.M.Campos, L.J.Appleman, M.Roche, A.Harris, M.V.Seiden, Massachusetts General Hospital, Boston,MA; Dana-Farber Cancer Institute, Boston,MA. A phase I trial of continual sequential oral etoposide and infusional topotecan. 2002; 21(ASCO2002):A:2168.
  72. M.Theodoulou, S.M.Campos, G.Batist, E.Winer, L.Norton, C.Hudis, L.Welles, Memorial Sloan-Kettering Cancer Center, New York,NY; Dana-Farber Cancer Institute, Boston,MA; Jewish General Hospital, McGill University, Montreal, QC, Canada; Elan Pharmaceuticals, Pinceton,NJ. TLC D99 (D,Myocet) Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. 2002; 21(ASCO 2002):A:216.
  73. Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 1; 92(5):1156-67.
    View in: PubMed
  74. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
    View in: PubMed
  75. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
    View in: PubMed
  76. S.M.Campos, R.T.Penson, U.A.Matulonis, R.S.Berkowitz, L.D.Duska, A.F.Fuller, A.K.Goodman, N.Nikrui, E.E.Sheets, M.Muto, K.M.MacNeill, J.C.Sivert, M.Roche, K.Wilson, J.G.Supko, M.V.Seiden, Dana-Farber Cancer Institute, Boston,MA; Massachusetts General Hospital, Boston,MA. A Phase II and Pharmacokinetic/Dynamic study of Doxil and weekly Paclitaxel chemotherapy for Rucurrent Mullerian Tumors. 2001; 20(ASCO 2001):A:2524.
  77. M.Theodoulou, S.M.Campos, L.Welles, G.Baptist, E.Winer, C.Hudis, Memorial Sloan-Kettering Cancer Center, New York,NY; Dana-Farber Cancer Institute, Boston,MA; The Liposome Company, Pinmceton, NJ; Jewish General Hospital (McGill Center for Translational Research), Montreal, Canada; Memorial-Sloan Kettering Cancer Center, New York, NY. Preliminary Cardiac Safety and Efficacy Data from Phase I/II Trial of TLC D-99 (D-99) and Trastuzumab (T) in patients withs locally advanced or Metastatic Breast CAncer (LABC/MBC). 2001; 20(ASCO 2001):A:180.
  78. U.Matulonis, S.M.Campos, L.Duska, A.Fuller, R.Falke, S.Gore, R.Berkowitz, M.Roche, D.Finkelstein, J.Sivret, T.Colella, R.Penson, E.Sheets, M.Seiden, Dana-Farber/Partners Cancer Care, Boston,MA; Harvard Vanguard Medical Associates, Boston,MA. Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. 2001; 20(ASCO 2001):A:846.
  79. S.M.Campos, R.Penson, U.Matulonis, R.Berkowitz, L.Duska, A.Fuller, A.Goodman, N.Nikrui, E.Sheets, M.Muto, K.MacNeill, C.Genovese. A Phase II and Pharmacokinetic/Dynamic Studyof Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Mullerian Tumors. 2000; 19(ASCO 2000):A:1623.
  80. H.Burstein, I.Kuter, P.Richardson, S.M.CAmpos, L.Parker, U.Matulonis, L.Harris, J.GArber, J.Younger, C.Bunnell, L.Shulman, E.Winer. Herceptin and Vinorelbine for HER-2 Positive Metastatic Breast Cancer: A Phase II Study. 2000; 19(ASCO 2000):A:392.
  81. A.Fuller, R.Penson, J.Supkp, U.Matulonis, R.Berkowitz, A.Goodman, S.Campos, K.MacNeill, K.Borden, S.Cook, S.Skates, M.Seiden. A Phase I/II Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recuurent Mullerian Tumors. 2000; 19(ASCO 2000):A:1552.
  82. C.Bunnell, L.Parker, U.Matulonis, L.Shulman, A.Elias, L.HArris, R. Scheib, H.Burstein, S.M.Campos, J.Younger, I.Kuter, E.Winer. A Phase I Study Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. 2000; 19(ASCO 2000):A:444.
  83. U.Matulonis, S.M.Campos, M.Seiden, A.Fuller, K.MacNeill, A.Charbonnier, R.Berkowitz, A.Goodman. Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. 2000; 19(ASCO 2000):A:1571.
  84. Botella-Estrada R, Sammartín O, Martínez V, Campos S, Aliaga A. Magnetic resonance angiography in the diagnosis of a case of giant cell arteritis manifesting as scalp necrosis. Arch Dermatol. 1999 Jul; 135(7):769-71.
    View in: PubMed
  85. S.M.Campos, R.Penson, K.MacNeill, R.Berkowitz, S.Cook, A.Fuller, A.Goodman, N.Najmosam, U.Matulonis, M.Seiden. A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer(ROC)(Meeting abstract). 1999; (ASCO 1999):A:1434.
  86. Campos SM, Walden T. Images in clinical medicine. Spigelian hernia. N Engl J Med. 1997 Apr 17; 336(16):1149.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Campos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_